TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC (OXRI)
A Phase II Clinical Study of Transarterial Chemoembolization (TACE) Plus Hepatic Arterial Infusion Chemotherapy (HAIC) With Oxaliplatin and Raltitrexed for Barcelona Stage C Hepatocellular Carcinoma (HCC)
Sponsor: Peking University Cancer Hospital & Institute
Listed as NCT04597970, this PHASE2 trial focuses on Hepatocellular Carcinoma and Transarterial Chemoembolization and remains ongoing. Sponsored by Peking University Cancer Hospital & Institute, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Oct 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Oct 2022 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.